Sarina Tanimoto Sells 100,000 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) insider Sarina Tanimoto sold 100,000 shares of the company’s stock in a transaction on Tuesday, April 16th. The stock was sold at an average price of $9.28, for a total transaction of $928,000.00. Following the transaction, the insider now owns 1,647,447 shares of the company’s stock, valued at approximately $15,288,308.16. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Sarina Tanimoto also recently made the following trade(s):

• On Friday, March 22nd, Sarina Tanimoto sold 2,343 shares of ARS Pharmaceuticals stock. The stock was sold at an average price of $9.02, for a total transaction of $21,133.86.
• On Thursday, March 14th, Sarina Tanimoto sold 444 shares of ARS Pharmaceuticals stock. The stock was sold at an average price of $9.00, for a total transaction of $3,996.00.
• On Wednesday, February 28th, Sarina Tanimoto sold 98,778 shares of ARS Pharmaceuticals stock. The shares were sold at an average price of $9.02, for a total transaction of $890,977.56.
• On Monday, February 26th, Sarina Tanimoto sold 700 shares of ARS Pharmaceuticals stock. The shares were sold at an average price of $9.01, for a total transaction of $6,307.00.

ARS Pharmaceuticals Trading Down 6.8 %

Shares of NASDAQ SPRY opened at $8.44 on Friday. The stock has a market cap of $814.48 million, a price-to-earnings ratio of -14.81 and a beta of 0.83. ARS Pharmaceuticals, Inc. has a 52 week low of $2.55 and a 52 week high of $11.27. The company’s 50-day moving average price is $8.73 and its 200 day moving average price is $6.25.

ARS Pharmaceuticals (NASDAQ:SPRY) last issued its quarterly earnings data on Thursday, March 21st. The company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.07. As a group, research analysts expect that ARS Pharmaceuticals, Inc. will post -0.69 earnings per share for the current year.

Institutional Investors Weigh In On ARS Pharmaceuticals

Large investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC acquired a new stake in shares of ARS Pharmaceuticals during the 1st quarter worth about $2,627,000. Squarepoint Ops LLC acquired a new stake in shares of ARS Pharmaceuticals during the 1st quarter worth about $84,000. State Street Corp boosted its stake in shares of ARS Pharmaceuticals by 50.4% during the 1st quarter. State Street Corp now owns 129,191 shares of the company’s stock worth $841,000 after purchasing an additional 43,300 shares during the last quarter. Jane Street Group LLC acquired a new stake in shares of ARS Pharmaceuticals during the 1st quarter worth about $895,000. Finally, Ameriprise Financial Inc. acquired a new stake in shares of ARS Pharmaceuticals during the 1st quarter worth about $1,825,000. 68.16% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

SPRY has been the subject of a number of research analyst reports. SVB Leerink upgraded shares of ARS Pharmaceuticals from a “market perform” rating to an “outperform” rating and increased their price target for the company from $6.00 to $18.00 in a report on Tuesday, March 5th. Leerink Partnrs upgraded shares of ARS Pharmaceuticals from a “market perform” rating to an “outperform” rating in a report on Tuesday, March 5th. William Blair upgraded shares of ARS Pharmaceuticals from a “market perform” rating to an “outperform” rating in a report on Tuesday, February 20th. Finally, Wedbush reiterated an “outperform” rating and issued a $19.00 price target on shares of ARS Pharmaceuticals in a report on Monday, March 11th.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.